在美国国会技术评价处(OTA)有关生物技术一系列报告的第一篇里提出,必须制定出新的法律,以消除人类组织样本所有权的混乱状况。报告提出,当把供应的细胞用来研制盈利的药物、诊断和研究器具时,出现了根本政策和伦理问题。例如,任何细胞供应者对于用他们的组织研制出来的细胞系 In the first article in a series of biotechnology reports by the U.S. Congressional Technical Evaluation Service (OTA), new laws must be put in place to eliminate the chaos of ownership of sample human tissues. The report suggests that fundamental policy and ethical issues arose when the cells supplied were used to develop profitable medicines, diagnostics and research devices. For example, any cell supplier to a cell line developed with their tissue